Immunic, Inc.

NasdaqCM:IMUX Stok Raporu

Piyasa değeri: US$203.8m

Immunic Yönetim

Yönetim kriter kontrolleri 3/4

Immunic CEO'su Daniel Vitt, Apr2019 tarihinde atandı, in görev süresi 7.08 yıldır. in toplam yıllık tazminatı $ 2.31M olup, şirket hissesi ve opsiyonları dahil olmak üzere 27.1% maaş ve 72.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.29% ine doğrudan sahiptir ve bu hisseler $ 586.25K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.8 yıl ve 5.5 yıldır.

Anahtar bilgiler

Daniel Vitt

İcra Kurulu Başkanı

US$2.3m

Toplam tazminat

CEO maaş yüzdesi27.05%
CEO görev süresi7.1yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresi4.8yrs
Yönetim Kurulu ortalama görev süresi5.5yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Oct 17

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jun 09

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Summary Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's significant drop appears to be an overreaction, given the positive disability progression data and clean safety profile. The company plans a Phase 3 trial focusing on confirmed disability progression, a key regulatory endpoint, to confirm these promising results. We reiterate our Strong Buy rating, viewing the stock dip as a buying opportunity for investors with high-risk tolerance. Read the full article on Seeking Alpha
Seeking Alpha • Apr 28

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Summary Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and recent stock dilution, Immunic's market cap remains low, suggesting significant upside if clinical trials succeed. Vidofludimus calcium's unique dual action offers neuroprotection and anti-inflammatory benefits, positioning it as a potential next-gen oral MS treatment. Financial risks include ongoing cash burn and potential dilution, but management has a track record of successful fund-raising to support R&D efforts. Read the full article on Seeking Alpha
Analiz Makalesi • Oct 25

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Jan 22

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Oct 13

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Jun 27

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 20

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic (NASDAQ:IMUX) on Thursday said a phase 1b trial of its psoriasis treatment IMU-935 failed to separate from placebo, as measured by a reduction in the severity of the psoriatic lesions in the patients. Shares of the micro-cap clinical-stage biopharma plunged 73.7% to $2.49 after hours. A pre-planned interim analysis of the early-stage trial found a greater decrease than expected in the so-called Psoriasis Area and Severity Index (PASI) in the placebo arm. The PASI is a widely used instrument in psoriasis trials that evaluates and grades the severity of psoriatic lesions and the patient's response to treatment. The trial enrolled a total of 41 patients who were randomized to get 150 mg once-daily and 150 mg twice-daily doses of IMU-935, along with placebo. "At this point, the company only has access to very limited information. The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period. Immunic does not yet have access to unblinded individual patient data," the company said in a statement. IMUX expects to continue IMU-935 development in psoriasis.
Seeking Alpha • Oct 10

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic (NASDAQ:IMUX) shares gained as much as 21% premarket on Monday after the clinical-stage biopharmaceutical company announced a $60M oversubscribed private placement equity financing. The company entered into a securities purchase agreement with select accredited investors and certain existing investors to issue and sell an ~8.69M shares of its common stock at $4.35/share and pre-funded warrants to purchase up to 5,096,552 common shares at $4.34/pre-funded warrant share. The pre-funded warrants will be immediately exercisable at $0.01 per share of common stock and remain exercisable until exercised in full. Gross proceeds from the equity financing is estimated to be around $60M. The financing is expected to close on Oct 12, 2022. Net proceeds will be used to fund Immunic's (IMUX) ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes. Proceeds, along with current cash, cash equivalents and marketable securities, is expected to fund operating and capital expenditures into Q4/2024.
Seeking Alpha • Aug 04

Immunic GAAP EPS of -$0.72 in-line

Immunic press release (NASDAQ:IMUX): Q2 GAAP EPS of -$0.72 in-line. Cash and Cash Equivalents as of Q2  $88.1 million.
Analiz Makalesi • Jul 27

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Tazminat Analizi

Daniel Vitt'un ücretlendirmesi Immunic'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$104m

Dec 31 2025US$2mUS$625k

-US$97m

Sep 30 2025n/an/a

-US$103m

Jun 30 2025n/an/a

-US$102m

Mar 31 2025n/an/a

-US$96m

Dec 31 2024US$3mUS$610k

-US$101m

Sep 30 2024n/an/a

-US$97m

Jun 30 2024n/an/a

-US$95m

Mar 31 2024n/an/a

-US$98m

Dec 31 2023US$1mUS$585k

-US$94m

Sep 30 2023n/an/a

-US$129m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$125m

Dec 31 2022US$3mUS$520k

-US$120m

Sep 30 2022n/an/a

-US$85m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$79m

Dec 31 2021US$2mUS$399k

-US$93m

Sep 30 2021n/an/a

-US$83m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$1mUS$381k

-US$44m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$39m

Dec 31 2019US$2mUS$202k

-US$35m

Tazminat ve Piyasa: Daniel 'nin toplam tazminatı ($USD 2.31M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.59M ).

Tazminat ve Kazançlar: Daniel 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Daniel Vitt (57 yo)

7.1yrs
Görev süresi
US$2,311,272
Tazminat

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic, Inc. since April 2019 and also served as its President until July 12, 2024. He is also managing director of Immunic Research GmbH in Ha...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Daniel Vitt
CEO & Director7.1yrsUS$2.31m0.29%
$ 586.2k
Jason Tardio
COO & President1.8yrsUS$1.21m0.0092%
$ 18.7k
Glenn Whaley
Chief Financial Officer6.1yrsUS$1.07m0.070%
$ 142.9k
Hella Kohlhof
Chief Scientific Officer9.3yrsVeri yokVeri yok
Jessica Breu
Vice President of Investor Relations & Communicationsno dataVeri yokVeri yok
Inderpal Singh
General Counsel4.9yrsVeri yokVeri yok
Patrick Walsh
Chief Business Officer4.6yrsVeri yokVeri yok
Werner Gladdines
Chief Development Officer1.8yrsVeri yokVeri yok
Michael A. Panzara
Chief Medical Officerless than a yearVeri yokVeri yok
4.8yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş

Deneyimli Yönetim: IMUX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Daniel Vitt
CEO & Director7.1yrsUS$2.31m0.29%
$ 586.2k
Barclay Phillips
Lead Independent Director6.5yrsUS$171.98k0.11%
$ 233.3k
Michael Bonney
Chair of the Boardno dataVeri yokVeri yok
Tamar Howson
Independent Director6.6yrsUS$149.82k0.11%
$ 233.3k
Jorg Neermann
Independent Director7.1yrsUS$156.98k0.15%
$ 299.2k
Paul Utz
Member of Scientific Medical Advisory Board5.5yrsVeri yokVeri yok
Duane Nash
Director7.3yrsUS$982.95k0.026%
$ 53.9k
Bruce Sands
Member of Scientific Medical Advisory Board5.5yrsVeri yokVeri yok
Fred Lublin
Member of Scientific Medical Advisory Board5.5yrsVeri yokVeri yok
Richard Rudick
Independent Director3.1yrsUS$149.48k0.17%
$ 344.6k
Jon Congleton
Independent Directorless than a yearVeri yokVeri yok
Simona Skerjanec
Independent Director1.8yrsUS$149.14kVeri yok
5.5yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: IMUX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/31 04:07
Gün Sonu Hisse Fiyatı2026/05/29 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Immunic, Inc. 18 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
George FarmerBMO Capital Markets Equity Research
William WoodB. Riley Securities, Inc.
Tyler BussianBrookline Capital Markets